BACKGROUND: Vorapaxar is indicated with standard antiplatelet therapy (APT) in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). OBJECTIVES: To evaluate the comparative effects of vorapaxar on platelet-fibrin clot characteristics (PFCC), coagulation, inflammation, and platelet and endothelial function during treatment with daily 81 mg aspirin (A), 75 mg clopidogrel (C), both (C + A), or neither. METHODS: Thrombelastography, conventional platelet aggregation (PA), ex vivo endothelial function by ENDOPAT, coagulation, platelet activation/inflammation marked by urinary 11-dehydrothromboxane B2 (UTxB2 ) and safety were determined in patients who were APT naïve (n = 21), on C (n = 8), on A (n = 29), and on A + C (n = 23) during 1 month of vorapaxar therapy and 1 month of offset. RESULTS: Vorapaxar had no effect on PFCC, ADP- or collagen-induced PA, thrombin time, fibrinogen, PT, PTT, von Willebrand factor (vWF), D-dimer, or endothelial function (P > .05 in all groups). Inhibition of SFLLRN (PAR-1 activating peptide)-stimulated PA by vorapaxar was accelerated by A + C at 2 hours (P < .05 versus other groups) with nearly complete inhibition by 30 days that persisted through 30 days after discontinuation in all groups (P < .001). SFLLRN-induced PA during offset was lower in APT patients versus APT-naïve patients (P < .05). Inhibition of UTxB2 was observed in APT-naive patients treated with vorapaxar (P < .05). Minor bleeding was only observed in C-treated patients. CONCLUSION: Vorapaxar had no influence on PFCC measured by thrombelastography, coagulation, or endothelial function irrespective of APT. Inhibition of protease activated receptor (PAR)-1 mediated platelet aggregation by vorapaxar was accelerated by A + C and offset was prolonged by concomitant APT. Vorapaxar-induced anti-inflammatory effects were observed in non-aspirin-treated patients.
BACKGROUND: Vorapaxar is indicated with standard antiplatelet therapy (APT) in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). OBJECTIVES: To evaluate the comparative effects of vorapaxar on platelet-fibrin clot characteristics (PFCC), coagulation, inflammation, and platelet and endothelial function during treatment with daily 81 mg aspirin (A), 75 mg clopidogrel (C), both (C + A), or neither. METHODS: Thrombelastography, conventional platelet aggregation (PA), ex vivo endothelial function by ENDOPAT, coagulation, platelet activation/inflammation marked by urinary 11-dehydrothromboxane B2 (UTxB2 ) and safety were determined in patients who were APT naïve (n = 21), on C (n = 8), on A (n = 29), and on A + C (n = 23) during 1 month of vorapaxar therapy and 1 month of offset. RESULTS: Vorapaxar had no effect on PFCC, ADP- or collagen-induced PA, thrombin time, fibrinogen, PT, PTT, von Willebrand factor (vWF), D-dimer, or endothelial function (P > .05 in all groups). Inhibition of SFLLRN (PAR-1 activating peptide)-stimulated PA by vorapaxar was accelerated by A + C at 2 hours (P < .05 versus other groups) with nearly complete inhibition by 30 days that persisted through 30 days after discontinuation in all groups (P < .001). SFLLRN-induced PA during offset was lower in APT patients versus APT-naïve patients (P < .05). Inhibition of UTxB2 was observed in APT-naive patients treated with vorapaxar (P < .05). Minor bleeding was only observed in C-treated patients. CONCLUSION: Vorapaxar had no influence on PFCC measured by thrombelastography, coagulation, or endothelial function irrespective of APT. Inhibition of protease activated receptor (PAR)-1 mediated platelet aggregation by vorapaxar was accelerated by A + C and offset was prolonged by concomitant APT. Vorapaxar-induced anti-inflammatory effects were observed in non-aspirin-treated patients.
Authors: Teddy Kosoglou; Larisa Reyderman; Renger G Tiessen; André A van Vliet; Robert R Fales; Robert Keller; Bo Yang; David L Cutler Journal: Eur J Clin Pharmacol Date: 2011-09-21 Impact factor: 2.953
Authors: K P Bliden; A Singla; M G Gesheff; P P Toth; A Tabrizchi; G Ens; K Guyer; M Singh; C J Franzese; D Stapleton; U S Tantry; P A Gurbel Journal: Thromb Haemost Date: 2014-04-24 Impact factor: 5.249
Authors: Paul A Gurbel; Kevin P Bliden; Kirk Guyer; Peter W Cho; Kazi A Zaman; Rolf P Kreutz; Ashwani K Bassi; Udaya S Tantry Journal: J Am Coll Cardiol Date: 2005-10-21 Impact factor: 24.094
Authors: Paul A Gurbel; Kevin P Bliden; Udaya S Tantry; Amy L Monroe; Adina A Muresan; Norman E Brunner; Carlos G Lopez-Espina; Peter R Delmenico; Eli Cohen; Gabriel Raviv; DeAnna L Haugen; Mark H Ereth Journal: Platelets Date: 2016-04-11 Impact factor: 3.862
Authors: Richard C Becker; David J Moliterno; Lisa K Jennings; Karen S Pieper; Jinglan Pei; Alan Niederman; Khaled M Ziada; Gail Berman; John Strony; Diane Joseph; Kenneth W Mahaffey; Frans Van de Werf; Enrico Veltri; Robert A Harrington Journal: Lancet Date: 2009-03-14 Impact factor: 79.321
Authors: Christian Schoergenhofer; Michael Schwameis; Georg Gelbenegger; Nina Buchtele; Barbara Thaler; Marion Mussbacher; Gernot Schabbauer; Johann Wojta; Petra Jilma-Stohlawetz; Bernd Jilma Journal: Thromb Haemost Date: 2018-06-04 Impact factor: 5.249
Authors: Kevin P Bliden; Udaya S Tantry; Martin G Gesheff; Christopher J Franzese; Shachi Pandya; Peter P Toth; Denny P Mathew; Rahul Chaudhary; Paul A Gurbel Journal: J Interv Cardiol Date: 2016-01-29 Impact factor: 2.279
Authors: Nga Nguyen; Christopher Garzia; Layla Van Doren; Elizabeth K Fletcher; Ryan Stevenson; David Jaramillo; Athan Kuliopulos; Lidija Covic Journal: Arterioscler Thromb Vasc Biol Date: 2020-12-03 Impact factor: 8.311
Authors: Mirjam Bachler; Lars M Asmis; Jürgen Koscielny; Thomas Lang; Hartmuth Nowak; Patrick Paulus; Jens-Christian Schewe; Christian von Heymann; Dietmar Fries Journal: Blood Coagul Fibrinolysis Date: 2022-06-08 Impact factor: 1.061
Authors: Athan Kuliopulos; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Susan E Turner; Kevin P Bliden; Elizabeth K Fletcher; Daniel H Cox; Lidija Covic Journal: Arterioscler Thromb Vasc Biol Date: 2020-10-08 Impact factor: 8.311